The aim was to compare treatment outcomes of clear cell metastatic renal cell carcinoma (ccmRCC) versus non-ccmRCC (nccmRCC) patients who received first-line immune combination therapies.
Within our retrospective multi-institutional consecutive database of eight tertiary-care centers, we identified mRCC patients treated with first-line immune combination therapies between 11/2017 and 12/2022. Using log-rank analysis and multivariable Cox regression, we tested for differences in overall survival (OS) and progression-free survival (PFS) of nccmRCC versus ccmRCC patients. Covariables consisted of age at diagnosis, sex, International Metastatic Renal Cell Carcinoma Database Consortium risk groups, Eastern Cooperative Oncology Group status, and sarcomatoid feature.
Of 289 study patients, 39 (13%) patients harbored nccmRCC. Median OS was 37 months versus not reached for ccmRCC versus nccmRCC patients (P = .6). Median PFS was 13 versus 15 months (P = .9). Multivariable Cox regression models did not identify nccmRCC as an independent predictor of higher overall mortality in mRCC patients (hazard ratio [HR]: 1.23; P = .6) or a higher progression rate (HR: 1.0; P = 1.0).
In our real-world multi-institutional study, no differences in OS and PFS between ccmRCC and nccmRCC patients receiving first-line immune combination treatment were observed, even after adjustment for important patient and tumor characteristics. More prospective trials in nccmRCC patients are needed.
Clinical genitourinary cancer. 2024 May 04 [Epub ahead of print]
Cristina Cano Garcia, Benedikt Hoeh, Subhajit Mandal, Severine Banek, Niklas Klümper, Philipp Schmucker, Oliver Hahn, Angelika Mattigk, Jörg Ellinger, Alexander Cox, Philippe Becker, Philip Zeuschner, Friedemann Zengerling, Kati Erdmann, Bjoern Thorben Buerk, Charis Kalogirou, Luka Flegar
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Electronic address: ., Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany., Department of Urology, Philipps-University Marburg, Marburg, Germany., Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany; Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany., Department of Urology and Paediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany., Department of Urology and Paediatric Urology, University Hospital Ulm, Ulm, Germany., Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany., Department of Urology and Paediatric Urology, Saarland University, Homburg/Saar, Germany., Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.